Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3977886 | Brachytherapy | 2012 | 11 Pages |
Abstract
HDR-ISBT may achieve good LC in gynecologic cancer unsuitable for ICB, especially in primary malignancies with a 2-year LC rate higher than 85%. Delivery of such high doses has potential advantages but may predispose to adverse effects, reversible in most cases.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Isabelle Thibault, Marie-Claude Lavallée, Sylviane Aubin, Nathalie Laflamme, Ãric Vigneault,